Summarized by Masters of Longevity from Longevity Docs News.
An autologous CD19 CAR T improved walking speed in 26 SPS patients at one year.
Key Takeaways
- Miv-cel showed a median 49% walking-speed improvement at one year.
- The trial was single-arm and open-label, which may bias results.
- Long-term safety risks from conditioning chemo remain unproven.
